MedTrace Logo

A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer

NCT06498518 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-07-11

No results posted yet for this study

Summary

Trial to investigate if the addition of two novel immunotherapy agents in combination with a chemotherapy agent can reduce the size of the cancer and how long they can delay the growth of the cancer in patients with metastatic pancreatic cancer.

Conditions

  • Neoplasms Pancreatic

Interventions

DRUG

IMM-101, Pembrolizumab, Gemcitabine

Patients will receive IMM-101, Pembrolizumab, Gemcitabine on a 3 week cycle

Sponsors & Collaborators

  • NHS Greater Glasgow and Clyde

    collaborator OTHER

  • University of Glasgow

    collaborator OTHER

  • Karen Carty

    lead OTHER

Principal Investigators

  • David Chang · University of Glasgow

  • Jeff Evans · University of Glasgow

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-17
Primary Completion
2025-05-23
Completion
2025-05-23

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06498518 on ClinicalTrials.gov